Xspray Pharma AB (XSPRAY) AI Stock Analysis

• Market Cap: kr1.19B
• Dividend Yield: N/A
• Average Volume (3M): 16.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: -19.44%
• Country: SE
• Employees: 27
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.14
• Shares Outstanding: 37,138,493
• 10 Day Avg. Volume: 15,501
• 30 Day Avg. Volume: 16,286
• PEG Ratio: 0.59
• Price to Book (P/B): 1.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Xspray Pharma AB's stock score reflects significant financial challenges, particularly the lack of revenue and increasing debt levels, which weigh heavily on the overall assessment. While technical indicators show some positive momentum, they are not strong enough to offset the financial concerns. The stock's valuation, characterized by a negative P/E ratio, underscores the company's unprofitability. To improve the stock's attractiveness, achieving revenue generation and financial sustainability will be critical.

Xspray Pharma AB Business Overview & Revenue Model

Company Description

Xspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.

How the Company Makes Money

Xspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.

Xspray Pharma AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.06M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-1.64M	-9.19M	-9.53M	-8.87M	-1.41M	-4.80M
	EBIT
-285.71M	-180.76M	-133.07M	-97.95M	-53.46M	-45.70M
	EBITDA
-275.20M	-169.81M	-122.13M	-87.82M	-50.99M	-40.90M
	Net Income Common Stockholders
-285.52M	-179.67M	-130.27M	-96.70M	-52.30M	-45.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
192.85M	166.30M	120.17M	271.88M	325.60M	209.87M
	Total Assets
307.38M	765.26M	585.43M	622.90M	605.30M	400.67M
	Total Debt
8.28M	36.81M	2.13M	3.23M	4.86M	5.33M
	Net Debt
-184.57M	-129.50M	-118.04M	-268.65M	-320.74M	-204.54M
	Total Liabilities
14.16M	71.85M	29.41M	31.15M	22.72M	26.96M
	Stockholders Equity
293.21M	693.41M	556.02M	591.75M	582.59M	373.71M
Cash Flow		Free Cash Flow
-264.51M	-257.38M	-238.47M	-147.57M	-145.00M	-126.23M
	Operating Cash Flow
-222.37M	-203.28M	-110.18M	-51.61M	-47.79M	-34.24M
	Investing Cash Flow
-42.14M	-65.88M	-135.34M	-105.82M	-96.83M	-91.99M
	Financing Cash Flow
306.11M	315.59M	93.81M	103.71M	260.35M	114.84M

Xspray Pharma AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Positive. The current price of 32 is above the 20-day moving average (MA) of 31.53, above the 50-day MA of 31.88, and below the 200-day MA of 39.56, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 50.60 is Neutral, neither overbought nor oversold. The STOCH value of 47.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XSPRAY.

Xspray Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	77 Outperform	kr1.26B	4.71	152.78%	―	1533.99%	―
XBRANE	54 Neutral	kr379.37M	―	-47.73%	―	45.52%	93.35%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
SYNACT	48 Neutral	kr917.45M	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.19B	―	-42.24%	―	―	-19.44%
IRLAB.A	40 Neutral	kr367.75M	―	-194.31%	―	1643.36%	50.36%
CANTA	31 Underperform	€289.38M	―	-167.55%	―	―	46.67%